|
MechanismProton pump inhibitors |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase 1 Study of Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)
Evaluate the safety of Secretrol® in patients undergoing endoscopic mucosal resection for early adenocarcinoma of the esophagus.
Phase 1 Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus
Secretrol administered over a 6 month period to patients with Barrett's Esophagus will be safe and well tolerated. Further, pH control will be evaluated in the distal esophageal mucosa and just below the squamocolumnar junction.
/ Unknown statusPhase 1/2 Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in Gastroesophageal Reflux Disease(GERD)Patients With Severe Erosive Esophagitis(EE).
To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.
100 Clinical Results associated with Effexus Pharmaceutical LLC
0 Patents (Medical) associated with Effexus Pharmaceutical LLC
100 Deals associated with Effexus Pharmaceutical LLC
100 Translational Medicine associated with Effexus Pharmaceutical LLC